Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

Pediatr Blood Cancer. 2015 Jun;62(6):1115. doi: 10.1002/pbc.25426. Epub 2015 Feb 3.

Authors

Lydia Benitez¹, Anthony J Perissinotti, Maressa Santarossa, Bernard L Marini

Affiliation

¹ Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan.

PMID: 25649118
DOI: 10.1002/pbc.25426

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Asparaginase / metabolism*
Humans
Male
Polyethylene Glycols / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*

Substances

Antineoplastic Agents
Polyethylene Glycols
Asparaginase